R.J. Lewis

💡If you can’t advertise, you can educate...👇    The foundation of #PharmaMarketing is shifting.    With FDA and HHS intensifying oversight of direct-to-consumer (DTC) advertising, agencies and pharma marketers face unprecedented uncertainty.  Recent high-profile ads flagged for misleading claims are just the beginning and billions in media investments could soon face compliance risk.    This is a moment that demands rethinking, not retreating.     The future of patient engagement lies in trusted, digital-first education that empowers patients rather than sells to them.    At Medlive - A PlatformQ Health Brand, we’ve seen firsthand how partnering with over 150 advocacy organizations—like National Organization for Rare Disorders and Asthma and Allergy Foundation of America — delivers outcomes that advertising cannot: improved communication with care teams, measurable practice change among clinicians, and patient confidence in decision-making.     Advertising may raise awareness, but education drives action. The question for pharma isn’t whether DTC will evolve, it’s whether or not you’re prepared for what comes next. 

18

1 Comment

Market Expansion strategies in Healthcare have blurred the line between patient care and customer acquisition. In discussion with Kim Witczak, Global Drug Safety Expert on market expansion, the creation of new disorders, and brand extensions. All have profound implications are profound. Let's ensure our strategies prioritize people over profit.

274

78 Comments

OS Therapies (NYSE-A: OSTX) reported Q1 2025 financial results and provided a business update, reaffirming progress on its regulatory and commercialization strategy for OST-HER2 in osteosarcoma and advancing multiple corporate and clinical initiatives. OS Therapies is a B2i Digital Featured Company. View their comprehensive profile at https://lnkd.in/epFNRZQB Highlights from today’s earnings release announcement include: - Feedback from the FDA’s Type D meeting is expected by mid-June to confirm statistical analysis plans supporting Accelerated Approval and Breakthrough Therapy Designation for OST-HER2. - OST-HER2 remains on track for a Q3 2025 Biologics License Application (BLA) submission for the prevention of recurrence in fully resected, lung metastatic pediatric osteosarcoma. - In Q1, the company completed the acquisition of three clinical-stage and eight preclinical assets from Ayala Pharmaceuticals, expanding its Listeria-based cancer immunotherapy pipeline. - OS Animal Health and OS Drug Conjugates subsidiaries were launched to commercialize canine osteosarcoma treatments and develop tunable antibody-drug conjugates, respectively. - The Company reported that operations are funded into mid-2026 and anticipates generating revenue from its animal health business as early as this year. Paul Romness, CEO of OS Therapies, noted, “The first quarter of 2025 was a crucial execution quarter for OS Therapies, as we announced positive data from our OST-HER2 Phase 2b clinical trial in the prevention of recurrent, fully resected, lung metastatic pediatric osteosarcoma and will be leveraging this data to seek Accelerated Approval from the FDA and other regulatory authorities. We believe we are well positioned to bring the first new treatment for osteosarcoma to market in over 40 years.” See the full announcement: https://lnkd.in/e7gsDdwg OST-HER2 is a listeria-based immunotherapy designed to stimulate an immune response against HER2-expressing cancer cells. It has demonstrated statistically significant results in recurrent, fully resected, lung metastatic osteosarcoma and has received RPDD, Fast Track, and Orphan Drug designations from the FDA. A Biologics License Application (BLA) is planned for submission in 2025. Led by CEO Paul Romness and an experienced executive team that includes Christopher Acevedo (CFO), Robert Petit (Chief Medical and Scientific Officer), John Doll (Chief of Staff), and Gerald Commissiong (Chief Business Officer), OS Therapies is focused on driving its pipeline forward to deliver potentially transformative treatments for osteosarcoma and other hard-to-treat cancers. Learn more about OS Therapies’ work at https://lnkd.in/eMc3JKG6 and visit B2i Digital for updates. For investor-related questions, please visit OS Therapies’ Investor Relations page or email irpr@ostherapies.com.

12

AI‑designed cancer drugs aren’t just theory anymore - they’re in the clinic and showing early signs of working. OncoC4, Inc.’s AI‑081 - a bispecific antibody targeting PD‑1 and VEGF - cleared FDA review late last year. Now they’ve already dosed the first patient in Phase 2 of their trial for advanced solid tumors. Why it’s worth watching: → Two targets, one drug – designed for cooperation, not just combination. → Signal at low dose - tumor response seen even at the smallest tested dose in Phase 1. → Potential efficiency leap – AI‑designed, high‑affinity antibodies could reach patients faster than traditional discovery allows. The bigger picture: Checkpoint inhibitors changed oncology. Anti‑angiogenesis drugs did too. Combining them into a single, purpose‑built molecule - designed in silico - could reshape how we think about efficacy, toxicity, and speed to market. If AI‑081 delivers in Phase 2, it won’t just be a win for OncoC4. It’ll be a proof point for AI‑designed multispecifics - and a signal that the “future of drug discovery” is happening now. Question is: who will get there first?

21

1 Comment

Is AI really killing your SEO or is your website just not ready for how AI actually works? In this clip from Answers with Ahava + Friends, Brad Muncs shares a practical tip on how healthcare marketers can improve their digital presence. 🎧 Want the full conversation? Link in the comments. 💬 Got a question you want featured? Drop it below. #AnswersWithAhava

17

2 Comments

🚀 Weekly ADC Insights: Regulatory, Clinical & Corporate Updates. The ADC pipeline is deeper and more diverse than ever. With expanding indications, advanced platforms, and fresh capital—2025 may redefine. Here are the latest highlights you shouldn't miss 👇 Exhibit#1: Companies with ADC and latest updates 🎯 Regulatory Milestones 🏅 Daiichi Sankyo US: ENHERTU sNDA filed in Japan for HER2+ metastatic solid tumors (4 pivotal Ph2 trials). 🧪 Kelun-Biotech: FDA cleared IND for SKB518 in the U.S.; Ph1 ongoing in China. 🧪 Keymed Biosciences: NMPA approved IND for CDH17 ADC (GI cancers); strong preclinical safety & efficacy. 💼 Corporate Developments 💰 Daiichi Sankyo US / AstraZeneca: DATROWAY off to a solid start—¥1.4B (~$10M) sales in HR+/HER2– mBC. 💰 Synthetic Design Lab: Raised $20M to scale SYNTHBODY™, enabling 10x improved payload delivery. 🤝 1STBIO x Ligachembio Sciences: Strategic R&D/licensing deal for 2–4 novel ADC payloads. 🏭 LOTTE BIOLOGICS: Opened $100M ADC CDMO facility in NY; first clinical contract secured. 📅 AACR 2025 Highlights 🔬 Innovent Biologics: IBI3010, IBI3014, and IBI3022 data in solid and gynecologic tumors. 🔬 Pfizer/Nona Biosciences: Presented PF-08052666 (TOP1i ADC) with strong preclinical activity in solid tumor models. Ph1 ongoing 🔬 NextPoint Therapeutics, Inc.: Unveiled NPX125 (B7H7 ADC) showing potent tumor regression; IND expected mid-2026. 🔬 Cantargia AB: Highlighted anti-IL1RAP ADC with robust tumor inhibition. 🔬 Zai Lab: ZL-6201 (LRRC15 ADC) showed strong tumor suppression; IND planned for 2025. 🔬 Zymeworks Inc.: Shared preclinical results on ZW327 (Ly6E ADC) and a biparatopic PTK7 ADC with strong internalization and activity. 🔬 Elevation Oncology: EO-1022 (HER3 ADC) demonstrated improved stability and reduced toxicity 🔬 ADC Therapeutics: Highlighted three exatecan-based ADCs (CLDN6, PSMA, ASCT2) potent and well tolerated. 🔬 Mythic Therapeutics, Inc.: MYTX-011 (cMET ADC) showed efficacy across multiple xenograft models. 🔬 Innate Pharma: IPH4502 (Nectin-4 ADC) outperformed EV in resistant UC. 🔬 SOTIO Biotech: Presented SOT109 (CDH17 ADC) and SOT106 (LRRC15 ADC) with potential across CRC and sarcomas. 🔬 Acepodia: Introduced dual-payload ADC platform (AD2C) targeting GPC3 in HCC. 🔬 Kowa Pharma: Demonstrated superior efficacy of K-679 (ultra-high-DAR ADUC) in EGFR+ tumors. 🔬 Debiopharm: Showcased Debio 1562M (CD37 ADC) with potency in AML/MDS and AbYlink™ conjugate platform. 🔬 GlycoNex Inc. : GNX1021 (branched Lewis B/Y ADC) exhibited activity in gastric ca with high tumor selectivity. 🔬 Alphamab Oncology: Presented bispecific ADCs — JSKN021 (EGFR/HER3) and JSKN022 (PD-L1/ITGB6/8) — strong tumor inhibition. 🔬 Precision Biologics, Inc. : PB-223 ADC (core 2 O-glycan target) demonstrated preclinical efficacy. 💬 Which ADCs do you think are poised for breakout success in 2025? Let’s explore together! ⬇️ #ADCs #Oncology #Biotech #PrecisionMedicine #PhenomiqsInsights #WeeklyUpdate #AACR2025

130

3 Comments

Boston Web Partners (a division of Trial AMPlify) is pleased to announce the launch of a new website for PRIA Healthcare. SEO best practices were incorporated to ensure high Google page rankings, and custom graphics were utilized to convey the solutions and processes more effectively. See this website redesign and others here: https://lnkd.in/eBZa-_yW

15

2 Comments

The real problem with healthcare marketing measurement isn’t attribution models.  It’s fragmentation. Most healthcare marketing stacks weren’t built to talk to each other. ❌ CRM data doesn’t inform bidding. ❌ Ad platforms optimize to shallow signals. ❌ And the outcomes that actually matter to the business sit downstream, disconnected. As Alex Kemp points out, when your CRM isn’t informing your ad platforms, you lose the ability to see what’s actually working or optimize where it matters. Richard Briddock takes it one step further: even when platforms do show performance, they’re often optimizing to the wrong outcome. Forms and calls may look good in-platform. But healthcare doesn’t grow on leads—it grows on booked and kept appointments. Watch the clip from the Scaling Up session “Building Strategic Investment Foundations” to hear how leading healthcare marketers are thinking differently about measurement. Full session link in the comments.

14

2 Comments